{"filing":{"accession_number":"0001140361-26-040377","cik":"0001228627","ticker":"IRD","company_name":"Opus Genetics, Inc.","form":"8-K","filing_date":"2026-10-21","report_date":"2026-10-19","primary_document":"ef20084050_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036126040377/ef20084050_8k.htm"},"events":[{"id":36730,"run_id":33864,"accession_number":"0001140361-26-040377","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Dr. Ashwath Jayagopal is transitioning from his role as Chief Scientific and Development Officer effective October 19, 2026. While the disclosure includes post-separation consulting arrangements and compensation details, the principal disclosed action is the departure of a named executive officer from an operational leadership position. The separation agreement and consulting terms are ancillary to the core event of his departure.","company_name":"Opus Genetics, Inc.","ticker":"IRD","filing_date":"2026-10-21","form":"8-K","submitted_at":null,"items":[{"id":41239,"accession_number":"0001140361-26-040377","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Dr. Ashwath Jayagopal is transitioning from his role as Chief Scientific and Development Officer effective October 19, 2026. While the disclosure includes post-separation consulting arrangements and compensation details, the principal disclosed action is the departure of a named executive officer from an operational leadership position. The separation agreement and consulting terms are ancillary to the core event of his departure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:21:27.985576+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41239,"accession_number":"0001140361-26-040377","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Dr. Ashwath Jayagopal is transitioning from his role as Chief Scientific and Development Officer effective October 19, 2026. While the disclosure includes post-separation consulting arrangements and compensation details, the principal disclosed action is the departure of a named executive officer from an operational leadership position. The separation agreement and consulting terms are ancillary to the core event of his departure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:21:27.985576+00:00","company_name":"Opus Genetics, Inc.","ticker":"IRD","filing_date":"2026-10-21"}]}